A recent study examined the financial burden of cancer care on different patient populations, revealing varying average annual costs and prescription spending. Uninsured patients topped the list with an average annual cost of $78,439, followed by Medicare patients at $67,979. VA/TRICARE patients had moderate costs but higher prescription spending at $56,619 and $16,758, respectively. Medicaid patients had the lowest total costs at $53,469. The study also highlighted the disparity in financial burden based on income levels, with low-income patients spending 11.71% of their annual income on prescriptions, compared to 5.89% for middle-income and 2.66% for high-income patients. The introduction of oncology biosimilars offers potential relief from this financial strain, providing a more affordable treatment option for cancer patients across different socioeconomic backgrounds.
Read more about this — here
